Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention

Details for Australian Patent Application No. 2004312376 (hide)

Owner Five Prime Therapeutics, Inc.

Inventors Hestir, Kevin; Masuoka, Lorianne; Lee, Ernestine; Bosch, Elizabeth; Pierce, Kristen; Wong, Justin G. P.; Chu, Keting; Williams, Lewis T.; Wang, Yan; Zeng, Changjiang

Agent Pizzeys

Pub. Number AU-A-2004312376

PCT Pub. Number WO2005/066211

Priority 60/531,230 19.12.03 US; 60/616,749 06.10.04 US; 60/538,349 21.01.04 US

Filing date 17 December 2004

Wipo publication date 21 July 2005

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 14/71 (2006.01) Peptides having more than 20 amino acids

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

3 August 2006 PCT application entered the National Phase

  PCT publication WO2005/066211 Priority application(s): WO2005/066211

15 July 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004312379-Systems, methods, and catalysts for producing a crude product

2004312372-Systems and methods of producing a crude product